In the past week, BTAI stock has gone down by -28.54%, with a monthly decline of -45.66% and a quarterly plunge of -68.54%. The volatility ratio for the week is 15.33%, and the volatility levels for the last 30 days are 9.74% for BioXcel Therapeutics Inc The simple moving average for the last 20 days is -39.88% for BTAI stock, with a simple moving average of -74.73% for the last 200 days.
Is It Worth Investing in BioXcel Therapeutics Inc (NASDAQ: BTAI) Right Now?
The 36-month beta value for BTAI is also noteworthy at 0.40. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BTAI is 31.83M, and at present, short sellers hold a 2.54% of that float. The average trading volume of BTAI on August 13, 2024 was 658.86K shares.
BTAI) stock’s latest price update
The stock price of BioXcel Therapeutics Inc (NASDAQ: BTAI) has plunged by -10.07 when compared to previous closing price of 0.73, but the company has seen a -28.54% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2024-08-09 that BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Vimal Mehta – Chief Executive Officer & Founder Vincent O’Neill – Executive Vice President, Chief of Product Development and Medical Officer Richard Steinhart – Senior Vice President and Chief Financial Officer Matt Wiley – Senior Vice President and Chief Commercial Officer Conference Call Participants Sumant Kulkarni – Canaccord Genuity Raghuram Selvaraju – H.C. Wainwright Operator Good morning, and welcome to the BioXcel Therapeutics Second Quarter 2024 Earnings Conference Call.
Analysts’ Opinion of BTAI
Many brokerage firms have already submitted their reports for BTAI stocks, with UBS repeating the rating for BTAI by listing it as a “Neutral.” The predicted price for BTAI in the upcoming period, according to UBS is $4 based on the research report published on February 21, 2024 of the current year 2024.
Mizuho, on the other hand, stated in their research note that they expect to see BTAI reach a price target of $4, previously predicting the price at $40. The rating they have provided for BTAI stocks is “Neutral” according to the report published on August 15th, 2023.
BTAI Trading at -46.61% from the 50-Day Moving Average
After a stumble in the market that brought BTAI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.57% of loss for the given period.
Volatility was left at 9.74%, however, over the last 30 days, the volatility rate increased by 15.33%, as shares sank -46.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -63.06% lower at present.
During the last 5 trading sessions, BTAI fell by -28.54%, which changed the moving average for the period of 200-days by -71.90% in comparison to the 20-day moving average, which settled at $1.0655. In addition, BioXcel Therapeutics Inc saw -77.71% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BTAI starting from Mehta Vimal, who sale 2,134 shares at the price of $1.28 back on Jun 17 ’24. After this action, Mehta Vimal now owns 47,539 shares of BioXcel Therapeutics Inc, valued at $2,739 using the latest closing price.
Yocca Frank, the Chief Scientific Officer of BioXcel Therapeutics Inc, sale 372 shares at $1.28 during a trade that took place back on Jun 17 ’24, which means that Yocca Frank is holding 13,474 shares at $476 based on the most recent closing price.
Stock Fundamentals for BTAI
Current profitability levels for the company are sitting at:
- -44.95 for the present operating margin
- 0.33 for the gross margin
The net margin for BioXcel Therapeutics Inc stands at -44.87. The total capital return value is set at -2.83. Equity return is now at value -1766.94, with -104.93 for asset returns.
Based on BioXcel Therapeutics Inc (BTAI), the company’s capital structure generated 3.56 points at debt to capital in total, while cash flow to debt ratio is standing at -1.02. The debt to equity ratio resting at -1.39. The interest coverage ratio of the stock is -7.72.
Currently, EBITDA for the company is -166.01 million with net debt to EBITDA at -0.46. When we switch over and look at the enterprise to sales, we see a ratio of 30.85. The receivables turnover for the company is 2.96for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.35.
Conclusion
In summary, BioXcel Therapeutics Inc (BTAI) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
